OBJECTIVES: Since2000, when the PCV7 (7-valent Pneumococcal Conjugate Vaccine) gradually went public, lots of cost-effectiveness evaluations on it have been done in Euro-American countries. In contrast, there is little economic review on PCV7 in Asian-Pacific region. This review comprehensively evaluated the cost and benefit of introducing PCV7 into the national immunization plan (evaluation include with and without the herd effect) of the Asia-Pacific region, to serve as a policy reference for the Asian-Pacific regions in their immunization plans. METHODS: All articles were identified from PubMed and Embase database between January 1st, 2002 and June 30th, 2013 in Korea, Hong Kong, Malaysia, Singapore, Australia and Japan. The following keywords were used: cost, cost-effectiveness, pneumococcal diseases and pneumococcal conjugate vaccine. Results were collected in terms of different assumptions, such as incidence ratios, vaccine uptake rate, and duration of protection and so on. Costs included both direct and indirect cost.  RESULTS: The clinical benefits and cost effective results varied from country to country. For illnesses avoided, the results varied between 4,030 and 30,040 per year. In terms of deaths avoided, the number of events varied between 14.2 and 643 per year. Studies that considered herd effects reported much more favorable cost-effectiveness than those that did not, with the ICERs U$5,929/LYG in Hong Kong, U$10,261/LYG in Malaysia, U$43,275/QALY in Singapore from social perspective. CONCLUSIONS: With respect to the WHO’s classification that an intervention is cost-effective if ICER is between 1 And 3 times of GDP, universal PCV7 vaccination would be considered cost-effective in Hong Kong, Malaysia and Singapore.